Skip to content

Evaluation of the Retinal Health Monitoring System Thickness Module

Evaluation of the Retinal Health Monitoring System - Retinal Thickness Module in Subjects With Normal Macular Thickness and Subjects With Center-involving Macular Edema

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04499703
Enrollment
60
Registered
2020-08-05
Start date
2020-11-11
Completion date
2021-01-25
Last updated
2021-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Edema, Macular Degeneration

Keywords

Age-Related Macular Degeneration, macular edema, retinal vein occlusion, diabetic macular edema

Brief summary

Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).

Detailed description

Evaluation of the Retinal Health Monitoring System - Retinal Thickness Module in subjects with normal macular thickness and subjects with center-involving macular edema.

Interventions

DEVICERHMS-RTM

Assessment of retinal thickness

DIAGNOSTIC_TESTSD-OCT

Assessment of retinal structure

Sponsors

Kubota Vision Inc.
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Age ≥50. 2. Corrected visual acuity (VA) of 20/125 or better, in the study eye(s) 3. Media clarity, undilated pupil size, and subject cooperation sufficient to obtain adequate OCT B-scans in the study eye(s) 4. Able to perform self-testing of retinal thickness with the RHMS-RTM after training 5. Able and willing to provide written informed consent before undergoing any study-related procedures 6. Group 1: Macula with normal thickness \[central subfield thickness (CST): \<305μm in women, and \<320μm in men as measured by Heidelberg Spectralis SD-OCT in at least one eye. Patients diagnosed with dry AMD are eligible for enrollment into Group 1. No history of wAMD, DR, or RVO in either eye 7. Group 2 and Group 3, in at least one and the same eye: History of center-involving macular edema due to wAMD (Group 2); or DR or RVO (Group 3); Macular edema on SD-OCT with CST ≥305 μm in women, and ≥320μm in men as measured by Heidelberg Spectralis SD-OCT.

Exclusion criteria

1. History of corneal refractive surgery \[e.g., laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), radial keratotomy (RK)\] in the study eye(s) 2. History of epiretinal membrane, vitreomacular traction, or macular hole in the study eye(s) 3. Participation in any study using an investigational drug within 30 days of screening or an investigational device within 60 days of screening 4. Refractive error within defined limits 5. History of photocoagulation laser scar or other retinal scar in the central 3 mm of the macula, in the study eye(s)

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of the RHMS-RTM retinal thickness measurements1 dayTo evaluate the ability of the RHMS-RTM device to measure retinal thickness

Secondary

MeasureTime frameDescription
Repeatability of RHMS-RTM retina thickness measurements1 dayTo assess repeatability of the RHMS-RTM device
Comparison of retinal thickness measurements between the RHMS-RTM and the SD-OCT1 dayTo evaluate the agreement of measurements by the RHMS-RTM and SD-OCT
Intraretinal and subretinal fluid detection1 dayTo evaluate the feasibility of intra- and sub-retinal fluid detection

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026